Rogalski Christina
Medical Business Development, edia. con gemeinnützige GmbH, Leipzig, Saxony, Germany.
Psoriasis (Auckl). 2015 Jun 8;5:97-107. doi: 10.2147/PTT.S63127. eCollection 2015.
One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.
A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review - efficacy, safety, and patient acceptability - was defined before checking the publications.
Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.
Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.
斑块型银屑病治疗的进展之一是卡泊三醇与倍他米松联合局部治疗。为了在一种双组分产品中提供这两种成分，人们努力将卡泊三醇和倍他米松结合起来，因为它们在同一制剂中时通常会失活。当发明了精心设计的载体成分（凝胶和软膏）后，这一问题得到了解决。本文综述了卡泊三醇/倍他米松二丙酸酯的疗效、安全性和患者可接受性。
对截至2015年2月发表的所有文章进行文献检索，包括最大的医学数据库。在查阅出版物之前，确定了用于评估本综述主要主题——疗效、安全性和患者可接受性——的检索策略。
共找到70篇参考文献并检查其相关性。在疗效方面，与单独使用单一药物治疗的组相比，双组分组中银屑病病情改善的患者比例总是显著更高。在安全性方面，固定组合通常与较低的不良事件风险相关。在患者可接受性方面，固定组合导致生活质量显著改善。与以前的治疗方法相比，双组分产品使用更方便且节省时间。
固定组合的卡泊三醇/倍他米松二丙酸酯是治疗身体和头皮轻至中度银屑病的一种有效且耐受性良好的药物，此外，还是一种基于证据的治疗方式。
